Search

A large group of countries constitute Latin American (LATAM) countries, where hemophilia care is as varied as the landscape of this region. To better understand the care provided to persons with bleeding disorders, especially hemophilia, a symposium was organized as part of the CLAHT Congress 2021 in Colombia to highlight the issues of hemophilia care and challenges faced by persons with hemophilia in four LATAM countries, Colombia, Peru, Argentina, and Mexico. A summary of the symposium is provided. Four clinicians highlighted the issues in their own country, the status, and the path forward to bring the standard of care to the international level in each of these countries. The geography of the country, the health infrastructure, and the resources available are obstacles in these countries to provide state-of-the-art care to the bleeding disorder community. However, depending on the country, its infrastructure and the resources available, progress is being made to upend the care provided. Indeed, the care of persons with hemophilia has been greatly improved, including personalized prophylaxis. The information summarized here first emphasizes how the geography of a country and the different healthcare infrastructures play a major role in how care is offered. It also provides a path for other countries to evaluate these issues in their own realities. In parallel, these data provide hope to many developing countries; despite obstacles, strides can be made in the care of the bleeding disorder community., Competing Interests: None of the authors received remuneration for the preparation of this manuscript. The views expressed in the manuscript are those of the authors alone. Giovanni G. DiMinno: Speaker or a member of a speaker bureau for Bayer, CSL Behring, Novo Nordisk, Pfizer, Sobi, Takeda; consultant or ad hoc speaker/consultant for Bayer, Novo Nordisk, Pfizer, Sanofi Aventis, Kedrion. Raul Bordone: Scientific advisory boards for CSL Behring, Novo Nordisk, Octapharma, Roche, Takeda; speaker honarariums from Kedrion, CSL Behring, Novo Nordisk, Octapharma, Roche, Takeda; support for Congress from Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Takeda. Juan Carlos Beltran: Kedrion Colombia SAS. Prasad Mathew: Kedrion SpA., (© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)